Dr P continues, as he showed yesterday in his tweet, that he sees Leronlimab as a great drug. And realistically , that’s where we are at today. there isnt much more he can do regardless if he was on friendly terms with NP or not. The shift now is to the advisory board and the new hires such as the CSO and the BLA expertise. These were major holes in the company that needed to be filled to get Leronlimab across the finish line for its first approval. The advisory board has “long tentacles “ in their areas of practice with other doctors so getting the word out will be helped by this team. The technical and process aspects of getting the drug approved will be handled by the new staff. I don’t believe these were areas where doctor P would have been able to help much anyway plus, he has his own business to focus in on which will be a handful . So it’s best , I believe, to look back and appreciate what he did for Leronlimab and for both parties to move forward in the directions they choose..